SK-OV-3 (also known as SKOV-3; SK.OV.3; SKOV3; Skov3 and SKO3) is an ovarian cancer cell line derived from the ascites of a 64-year-old Caucasian female with an ovarian serous cystadenocarcinoma.[1] The SK-OV-3 cell line is also hypodiploid, with a modal number of chromosomes of 43 (range 42-45), occurring in 63.3% of cells. SK-OV-3 are positive for many of the antigens used to identify cancers of epithelial origin in clinical practice, including vimentin (VIM), high molecular weight cytokeratin (HMWK), low molecular weight cytokeratin (LMWK), epithelial membrane antigen (EMA) and leucocyte common antigen (LCA).[2]

Use in Research

Early work by Fogh, J. in 1986 showed that SK-OV-3 cells do not express the MUC16 (CA125) mucin antigen (that later became the most frequently used biomarker for ovarian cancer detection) and also showed using dose-response curves that SK-OV-3 were platinum sensitive.[3][4] It was subsequently shown that ectopic expression of the MUC16 C-terminal domain in SK-OV-3 cells decreases their sensitivity to cisplatin-induced apoptosis.[5]

SK-OV-3 have been shown to produce large solid tumours (>1.5 cm^3) when injected into nude mice, with tumours loosely adhering to fat in the pelvic region, intestines and/or omentum.[6]

This cell line is also part of the NCI-60 cancer cell line panel used by the National Cancer Institute.

References

  1. ↑ Jørgen Fogh, Jens M. Fogh, Thomas Orfeo; One Hundred and Twenty-Seven Cultured Human Tumor Cell Lines Producing Tumors in Nude Mice, JNCI: Journal of the National Cancer Institute, Volume 59, Issue 1, 1 July 1977, Pages 221–226, https://doi.org/10.1093/jnci/59.1.221.
  2. ↑ Shaw, T.J., Senterman, M.K., Dawson, K., Crane, C.A. and Vanderhyden, B.C., 2004. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Molecular therapy, 10(6), pp.1032-1042.
  3. ↑ Suh KS, Park SW, Castro A, Patel H, Blake P, Liang M, Goy A (Nov 2010). "Ovarian cancer biomarkers for molecular biosensors and translational medicine". Expert Review of Molecular Diagnostics. 10 (8): 1069–83. doi:10.1586/erm.10.87. PMID 21080822.
  4. ↑ Fogh, J., 1986. Human tumor lines for cancer research. Cancer investigation, 4(2), pp.157-184.
  5. ↑ Boivin, M., Lane, D., Piché, A. and Rancourt, C., 2009. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecologic oncology, 115(3), pp.407-413.
  6. ↑ Shaw, T. J., Senterman, M. K., Dawson, K., Crane, C. A. and Vanderhyden, B. C., 2004. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Molecular therapy, 10(6), pp.1032-1042.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.